GlassScriptPhysician profile
Jennifer Russo
NPI 1699032128
$1,635.35
in general payments reported to CMS, 2019-2025
21 companies · $588 in 2025
The $588 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $178 · 2024: $870 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,635.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $395.78 | 2023-2025 | Tremfya, Simponi Aria |
| Amgen INC. | $205.31 | 2024-2025 | Enbrel, Otezla, Evenity |
| Shape Memory Medical INC. | $151.64 | 2025 | Impede Embolization Plug |
| Ucb, INC. | $146.14 | 2024-2025 | Bimzelx, Cimzia |
| Exact Sciences Corporation | $110.78 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $81.92 | 2024 | Veozah |
| Lilly USA, LLC | $74.80 | 2024 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $63.79 | 2024-2025 | Rybelsus, Ozempic |
| Medline Industries LP | $50.00 | 2025 | |
| Abbvie INC. | $46.01 | 2024-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $44.94 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $44.58 | 2024 | Orencia |
| Fresenius Kabi USA, LLC | $42.69 | 2024 | Idacio |
| Ardelyx, INC. | $35.81 | 2024-2025 | Ibsrela |
| Radius Health, INC. | $33.32 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $23.12 | 2025 | Venaseal |
| Scilex Pharmaceuticals INC. | $20.62 | 2025 | |
| Novartis Pharmaceuticals Corporation | $19.24 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $16.84 | 2024 | Farxiga |
| Phathom Pharmaceuticals, INC. | $14.39 | 2024 | Voquezna |
| Pfizer INC. | $13.63 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Russo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.